Staffan Strömberg, Ph.D.
CEO since 2013. Born 1967.
Staffan has over 20 years of experience in the pharmaceutical industry. Besides his role as Head of Medical Devices at the Swedish Medical Products Agency, he has also been Vice President of Nicox France, and had management positions at AstraZeneca. Staffan has particularly experience in the development of orphan drugs as he was Head of R&D of Swedish Orphan.
Shareholding in the Company: 76,728 shares of series B and 70,000 warrants and 45,864 shares of series B through the wholly-owned company Eteboxagu AB.
Eamonn Connolly, Ph.D.
Chief Scientific Officer since 2013. Born 1957.
Eamonn is the former VP Research of BioGaia, with 15 years experience working with pre-clinical and clinical research on live bacterial therapies. He has earlier extensive experience from the pharmaceutical industry including leading positions in R&D at Kabi Vitrum, Pharmacia & Upjohn and Fresenius Kabi.
Shareholding in the Company: 56,864 shares of series B and 50,000 warrants.
Chief Financial Officer since 2017. Born 1974.
Daniel has 20 years experience from diverse U.S. and international management positions in finance and accounting with Investors Bank & Trust Co., Nordea Investment Management AB and Nordea Bank AB.
Shareholding in the Company: 5,972 shares of series B and 50,000 warrants.
Anders Kronström, M.Sc., M.B.A.
Chief Operating Officer Since 2018. Born 1967.
Anders Kronström has over 20 years of experience working in the pharmaceutical industry. His experience spans across all stages of drug development in different disease segments. During his career at AstraZeneca he has had senior leadership positions within Project Management and Business Development. More recently, he was a CEO of Biosergen AS, a Norwegian biotechnology company.
Shareholding in the Company: 170 shares of series B.
Agneta Heierson, Ph.D.
Vice President Clinical Development
Agneta has over 25 years of experience working in the pharmaceutical industry. Most recently she has been the Global Vice President, R&D Supply Chain at AstraZeneca. Her extensive experience includes leading both global cross-functional drug development projects across all phases of development in different therapeutic areas, as well as leading clinical and pharmaceutical development organizations.
Michael Owens, B.S.B.A.
Michael has a background as Auditor at Arthur Andersen & Co. and Ernst & Young AB. He has held the position as CFO at Vitamex AB and as Financial Controller at Karolinska Development AB. Michael has 30+ years experience of finance of which two decades in the Nutritional Supplements and early stage Life Science industries.
Paul Alhadeff, B.Sc.
Head of Pharmaceutical Development and Manufacturing
Paul has more than two decades of experience in pharmaceutical development starting at Kabi Vitrum in 1989. During his career at AstraZeneca he has worked to bring several new drugs to the market, including Oxeeze Turbohaler and Symbicort.
Christine Nguy, Pharm.D., M.Sc.
Business Development Manager
Christine is a trained pharmacist specialised in industrial pharmacy with education and experience in bioentrepreneurship.
Leif Gallo, LL.M.
Leif has extensive experience in the pharmaceutical industry as in-house counsel with global and managerial responsibilities (AstraZeneca, Orexo).
Crescent Yingyue Liao, M.Sc.
Crescent holds a Bachelor's degree in Biochemistry and a Master's degree in Bioentrepreneurship.
Patrick Beke, M.Sc.
Patrick has an education in biomedical science and oncology. He has experience in academic research and managerial experience in primary patient care.